Asian Cardiovasc Thorac Ann 2003;11:189
© 2003 Asia Publishing EXchange Ltd
Acromegaly as Manifestation of a Bronchial Carcinoid Tumour
Pier Luigi Filosso, MD,
Giovanni Donati, MD,
Ottavio Rena, MD,
Alberto Oliaro, MD
University of Torino Italy, San Giovanni Battista Hospital, Department of Thoracic Surgery, Via Genova, 3 10126 Torino Italy
We read with interest the paper of Bhansali and Coll.1 Acromegaly as manifestation of a bronchial carcinoid tumour is really rare, and no more than 50 cases are to date described in English literature.
We have some questions for the Authors:
- - the pulmonary lesion described is a very large and centrally located within the right lung. Diagnosis of bronchial carcinoid was obtained by a transbronchial lung biopsy. But no data are presented about the endobronchial location of the tumour, and the possible presence of mediastinal lymph node enlargementat the thoracic CT scan;
- - the Authors did not perform a preoperative whole boby.111In-DTPA-pentreotide scintigraphy (Octreoscan), which is recognized to be effective in detecting possible mediastinal or distant metastases of neuroendocrine tumours;
- - an upper right lobectomy was performed: did the patient underwent a radical mediastinal and hilar lymphadenectomy?
- - the tumour was assessed as bronchial carcinoid: was it typical or atypical one?
- - a complete immunohistochemical assessment of the neoplasm was performed; in particular somatostatin receptors were detected. Which kind of somatostatin receptors subtype did Authors find?
We have observed2 one patient with a pT2N0 typical bronchial carcinoid associated with acromegaly, and two with Cushings syndrome; in all cases, both acromegaly and Cushings syndrome disappeared with the resection of the tumour.
One patient presented a mediastinal recurrence of ACTH producing carcinoid, promptly detected with Octreoscan.3
In vivo expression of somatostatin receptors is provided by Octreoscan;4 thus tumours expressing a high quantity of these receptors can be easily detected with this technique. Plus, a positive Octreoscan can justify a medical treatment with long-acting somatostatin analogy (octreotide-lanreotide).
In conclusion we emphasize the use of 111In-DTPA-pentreotide scintigraphy in the preoperative evaluation of patients with histologically proven neuroendocrine lung tumours, and in their follow-up.
We suggest to the use of octreotide in the treatment of recurrences or distant metastases of these neoplasm.5
REFERENCES
- Bhansali A; Rana DM; Bhattacharya S; Muralidraran R; Dash R; Banerjee AK: Acromegaly: a rare manifestation of bronchial carcinoid. Asian Cardiovasc Thorac Ann
. 2002;10:2736.[Abstract/Free Full Text]
- Filosso PL; Rena O; Donati G; Casadio C; Ruffini E; Papalia E; Oliaro A; Maggi G: Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg
2002;123:3039.[Abstract/Free Full Text]
- Filosso PL; Rena O; Ruffini E; Oliaro A: Ectopic ACTH-producing tumors of the chest and octreotide scintigraphy. Eur J Cardio-thorac Surg
2002;21:1126.[Free Full Text]
- Kwekkeboom DJ; Siang Kho G; Lamberts SWJ: The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med
1994;21:1106.[Medline]
- Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O: long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardio-thorac Surg
2002;21:9137.[Abstract/Free Full Text]